Skip to main content

Table 2 Summary of adverse events (All causality)

From: Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

 

All adverse events

Grade 3–4 adverse events

During infusional + 1 hour

5 (14%)

0

Fatigue

22 (50%)

2 (4.5%)

Diarrhea

21 (48%)

3 (7%)

Rash

18 (41%)

0

Decreased appetite

16 (36%)

0

Nausea/Vomiting

15 (34%)

0

Pruritus

12 (27%)

0

Dehydration

2 (4.5%)

2 (4.5%)

Thrombocytopenia

1 (2%)

1 (2%)

  1. This table includes all events that occurred in greater than 10% of patients (any grade), or that occurred in at least 2 patients at grade ≥3, or that occurred in any patient at grade 4.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us